Bert F, Larroque B, Dondero F, Durand F, Paugam-Burtz C, Belghiti J, Moreau R, Nicolas-Chanoine M-H
Service de Microbiologie, Hôpital Beaujon, AP-HP, Clichy, France.
Transpl Infect Dis. 2014 Feb;16(1):84-9. doi: 10.1111/tid.12169. Epub 2013 Dec 16.
The aim of the study was to identify risk factors associated with pre-transplant fecal carriage of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae in liver transplant recipients.
Over a 3-year period (January 2009-December 2011), 317 patients who underwent liver transplantation were screened preoperatively for fecal carriage of ESBL-producing Enterobacteriaceae. Risk factors for fecal carriage were investigated by univariate analysis and stepwise logistic regression.
Of the 317 patients screened, 50 (15.7%) harbored an ESBL-producing isolate. Previous infection with an ESBL-producing organism had developed during the last 6 months in 20% of fecal carriers versus in none of the non-carriers. Other variables associated with fecal carriage were a model for end-stage liver disease score ≥25, pre-transplant stay in the intensive care unit ≥48 h, hospital stay ≥10 days in the last 6 months, a history of spontaneous bacterial peritonitis (SBP), exposure to a β-lactam agent in the last month, and prophylaxis with norfloxacin. Independent predictors of fecal carriage in the multivariate logistic regression model were exposure to a β-lactam agent in the month preceding transplantation (odds ratio [OR] = 7.8, confidence interval [CI] = 4-15.5, P < 0.001), and a history of SBP (OR = 2.4, CI = 1.1-4.9, P = 0.02).
Previous infection with an ESBL-producing isolate, recent exposure to a β-lactam agent, and a history of SBP are risk factors for preoperative fecal carriage of ESBL-producing Enterobacteriaceae in liver transplant recipients. Patients at risk of fecal carriage should receive intraoperative prophylaxis and, when necessary, empiric postoperative antimicrobial treatment that includes coverage for these organisms.
本研究旨在确定肝移植受者移植前产超广谱β-内酰胺酶(ESBL)肠杆菌科细菌粪便携带相关的危险因素。
在3年期间(2009年1月至2011年12月),对317例行肝移植的患者术前进行产ESBL肠杆菌科细菌粪便携带情况筛查。通过单因素分析和逐步逻辑回归研究粪便携带的危险因素。
在筛查的317例患者中,50例(15.7%)携带产ESBL菌株。20%的粪便携带者在过去6个月内曾感染产ESBL生物体,而非携带者均无感染。与粪便携带相关的其他变量包括终末期肝病模型评分≥25、移植前在重症监护病房停留≥48小时、过去6个月住院时间≥10天、自发性细菌性腹膜炎(SBP)病史、过去1个月接触β-内酰胺类药物以及诺氟沙星预防用药。多因素逻辑回归模型中粪便携带的独立预测因素为移植前1个月接触β-内酰胺类药物(比值比[OR]=7.8,置信区间[CI]=4-15.5,P<0.001)和SBP病史(OR=2.4,CI=1.1-4.9,P=0.02)。
既往感染产ESBL菌株、近期接触β-内酰胺类药物以及SBP病史是肝移植受者术前产ESBL肠杆菌科细菌粪便携带的危险因素。有粪便携带风险的患者应接受术中预防,必要时接受经验性术后抗菌治疗,包括覆盖这些生物体。